JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v7i6.5632ArticleClinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis Bhttps://artdesignp.com/journal/JCNR/7/6/10.26689/jcnr.v7i6.5632YangQian2023762023-11-27Objective: To explore and analyze the clinical efficacy and incidence of adverse reactions of entecavir combined with long-acting interferon in treating hepatitis B. Methods: The study was conducted from January 2020 to December 2022, and the research subjects were 69 hepatitis B patients admitted to our hospital. The patients were divided into a research group (n = 35) and a control group (n = 34). Patients in the control group were treated with entecavir, while patients in the study group were treated with entecavir combined with long-acting interferon. The antiviral efficacy, liver function indicators, clinical effectiveness, and incidence of adverse reactions were compared between the two groups. Results: The HBV-DNA negative conversion rate and HBeAg seroconversion rate of the patients in the study group were higher than those of the control group, and the virological breakthrough rate was lower than that of the control group (P < 0.05); the alanine transaminase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) levels of the patients in the study group were all lower after treatment. In the control group, the albumin (ALB) level was higher than that in the control group (P < 0.05). The clinical effective rate of patients in the study group was higher than that in the control group (P < 0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The treatment effect of entecavir combined with long-acting interferon in patients with hepatitis B is significant. It can effectively antiviral and improve the liver function of patients. The incidence of adverse reactions is low and can be promoted and applied.

Hu D, 2022, Study on the Clinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in the Treatment of Hepatitis B. Medical Diet and Health, 20(7): 48–50 + 58.

Tang X, 2021, Effects of Entecavir Combined with Interferon on Liver Function and HBV-DNA Negative Conversion Rate in HBeAg-Positive Chronic Hepatitis B Patients. Primary Medicine Forum, 25(14): 2011–2013.

Si Q, 2023, Clinical Efficacy and Safety Observation of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis B. Clinical Research, 31(3): 73–75.

Yan H, Bai H, Liu J, et al., 2021, Effects of Entecavir Combined with Pegylated Interferon on Viral Dynamics and Safety in Patients with Chronic Hepatitis B Fibrosis. Medical Theory and Practice, 34(6): 958–959.

Zhang Y, Lu Q, Cao H, et al., 2021, Clinical Efficacy of Entecavir Combined with Interferon in Treating Hepatitis B Cirrhosis and its Impact on Liver Fibrosis and Cellular Immune Function. Modern Chinese Doctors, 59(23): 83–86.

Zhou C, Yu W, Chen W, et al., 2020, Effects of Pegylated Interferon Alpha-2b Combined with Entecavir on ROR?t eGFR in Patients with Chronic Hepatitis B. Hebei Medicine, 26(12): 2087–2091.

Zhang Y, 2020, Effect and Safety Analysis of Pegylated Interferon-Based on Entecavir on Antigen Seroconversion in Patients with Hepatitis B. Heilongjiang Medicine, 44(12): 1675–1677.

Wang Z, 2020, Effect of Peginterferon Alpha-2a Combined with Entecavir on Liver Fibrosis in Patients with Chronic Hepatitis B. Modern Diagnosis and Treatment, 31(8): 1228–1230.

Li J, Dong J, Dong Z, et al., 2023, Effects of Pegylated Interferon Alpha-2a Combined with Entecavir on Relevant Indicators in Patients with Chronic Hepatitis B. Journal of Practical Clinical Medicine, 27(2): 92–96.

Gu Y, 2019, Observation on the Effect of Pegylated Interferon + Entecavir in Treating Chronic Hepatitis B and the HBeAg Negative Conversion Rate. Electronic Journal of Cardiovascular Diseases of Integrated Traditional Chinese and Western Medicine, 7(7): 76–77.

Tang M, Tang J, 2021, Comparison of the Effects of Tenofovir and Entecavir in Treating Hepatitis B Virus-Positive Chronic Hepatitis with Poor Interferon Effect. Heilongjiang Medicine, 45(23): 2554–2556.

Jin J, 2016, Clinical Research on Sequential Entecavir Therapy and Pegylated Interferon in Treating Chronic Hepatitis B. Primary Medical Forum, 20(36): 5115–5116.

Fu P, Yao H, 2016, Effect of Entecavir Combined with Interferon in Treating Chronic Hepatitis B on Serum Fibrosis Indicators in Patients. Primary Medicine Forum, 20(35): 4938–4939.

Fu P, Yao H, 2016, Research on Sequential Entecavir Therapy and Peginterferon in Treating Chronic Hepatitis B. Primary Medicine Forum, 20(31): 4393-4394.

Zhao H, Chen T, Li Y, et al., 2021, Observation on the Clinical Curative Effect of Entecavir Combined with Pegylated Interferon Alpha-2b in HBeAg-Negative Chronic Hepatitis B Patients. Contemporary Medicine, 27(21): 96–98.